Harbour BioMed and Kelun-Biotech receive China IND approval for asthma therapy

​

Harbour BioMed and Kelun-Biotech have received approval from China’s NMPA for their IND application for the HBM7575/SKB575 bispecific antibody intended to treat asthma.

The post Harbour BioMed and Kelun-Biotech receive China IND approval for asthma therapy appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.